Drug Pricing
KEI Reaction to the White House CEA Paper on Biopharmaceutical Pricing Home and Abroad
On February 9, 2018, the Trump Administration released a paper by the Counsel of Economic Advisers (CEA) on drug pricing. The paper on pricing was thought to have been led by economist Tomas Philipson, appointed to the CEA by President… Continue Reading
Commentary on Hillary Clinton’s Plan to Respond to Unjustified Price Hikes for Long-Available Drugs
Democratic presidential nominee Hillary Clinton has published a factsheet presenting, “Hillary’s Plan to Respond to Unjustified Price Hikes for Long-Available Drugs.”
Today via Twitter, KEI Director James Love offered a six point commentary on Secretary Clinton’s proposal to address drug price hikes:
Seminars on Drug Pricing: Part 1, Paul Grootendorst
Today, KEI hosted the first talk in a series of seminars on drug pricing. The seminar, conducted via video conference, focused on the Canadian approach to drug pricing. Each seminar in the series is intended to contribute to the discussion on drug pricing and how we can improve affordability and access to medicines. Paul Grootendorst began with a presentation (the slides are available here), before opening up the discussion to questions from those participating in the video conference.
KEI Seminars on Drug Pricing: 30 April 2015, Prof. Paul Grootendorst on the Canadian approach to drug pricing
On Thursday, 30 April 2015, KEI will host the first talk in a series of seminars on drug pricing. The seminars will take place via video conference (hosted by KEI), and participation is welcome either by attending the presentation at KEI’s Washington, DC offices, or to the extent we are able, joining the digital conference.
Transcript of Bayer CEO Marjin Dekkers quote at the December 3, 2013 FT Event, regarding India compulsory license of Nexavar
On January 21, 2014, Ketaki Gokhale of Bloomberg published a story in Businessweek on disputes over drug patents. The story closed with a rather sinister quote attributed to Bayer CEO Marijn Dekkers, “We did not develop this medicine for Indians. Continue Reading